Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
Jiayin Group Fourth Quarter 2025 Earnings Call - Compliance-first pivot, short-term shrinkage for longer-term quality growth
Jiayin told investors it chose defense over offense in the new regulatory era, tightening borrower intake and reworking risk controls even as volumes and near-term margins fell. Management highlighted...
- Management adopted a compliance-first strategy after new regulation, deliberately tightening borrower acquisition and underwriting to protect asset quality.
- Full-year 2025 loan facilitation volume was reported at RMB 129 billion, roughly +28% year-on-year according to management remarks.
- Q4 2025 facilitation volume declined to RMB 24.2 billion, down 12.6% year-on-year; Q4 net revenue was RMB 1,090.2 million, down 22.4% year-on-year.
- +12 more takeaways
DiaMedica Therapeutics Full Year 2025 Earnings Call - Preeclampsia signal: BP reduction, no placental crossing, Phase II expansion
DiaMedica reported 2025 progress driven by DM199, a recombinant KLK1, with the clearest near-term readout coming from investigator-sponsored preeclampsia work. Interim Part 1-A data showed dose-depend...
- Interim Part 1-A preeclampsia data showed dose-dependent, statistically significant reductions in systolic and diastolic blood pressure in hypertensive women expected to deliver within 72 hours.
- DM199 significantly reduced uterine artery pulsatility index, a Doppler measure that suggests improved utero-placental perfusion and lower vascular resistance.
- Safety signal notable: DM199 did not cross the placental barrier in the patients studied, and no passage into breast milk was detected, strengthening maternal-only exposure profile.
- +11 more takeaways
IZEA Q4 2025 Earnings Call - Strategic Pivot Delivers Break-even and $50.9M Cash
IZEA says 2025 was a reset year and the numbers back it up. Annual revenue fell to $31.2 million, down 13% as management deliberately off-boarded lower-margin SMBs and exited international markets, bu...
- Company executed a deliberate strategic pivot in 2025, prioritizing enterprise accounts and off-boarding lower-margin SMBs and international operations.
- Annual revenue was $31.2 million in 2025, down 13% year-over-year, reflecting the intentional repositioning and macro headwinds.
- Q4 2025 revenue was $6.1 million, a 45% decline year-over-year, with management saying more than half the decline came from strategic client rationalization.
- +11 more takeaways
RenovoRx Q4 2025 Earnings Call - Commercial ramp ahead as TIGeR-PaC nears enrollment
RenovoRx closed 2025 as a fledgling commercial company, generating $1.1 million for the year and $238,000 in Q4 while converting early clinical users into paying customers. Management says the busines...
- Q4 2025 revenue was $238,000, full-year 2025 revenue totaled $1.1 million, reflecting an early, concentrated commercial footprint.
- RenovoRx reports a very high gross margin in Q4, 88% gross margin on product revenue for the quarter.
- As of February 27, 2026, 12 U.S. cancer centers are actively using RenovoCath, and another 21 centers are evaluating or preparing for activation, a near-term pipeline of 33 centers.
- +12 more takeaways
Innventure Q4 2025 Earnings Call - Platform crosses from potential to performance as Accelsius books $50M+ and targets cash flow breakeven in 2026
This call was a stop-the-presses moment for Innventure. Management argues the business has moved from thesis to proof, with three operating companies simultaneously hitting commercial inflection point...
- Management frames Q4 2025 and Q1 2026 as a structural inflection, claiming the platform has moved from potential to demonstrable performance across multiple operating companies.
- Accelsius booked over $50 million of contracted backlog in Q1 2026, described as production-volume orders rather than pilots, providing leading visibility into 2026 revenue growth.
- Innventure expects Accelsius to exit 2026 cash flow breakeven, implying a December 2026 annual revenue run rate of roughly $100 million, with revenue skewed to the back half of the year due to supply chain timing.
- +17 more takeaways
Virgin Galactic Q4 2025 Earnings Call - First spaceship assembled; commercial service on track for Q4 2026 with sales reopened at $750,000
Virgin Galactic reported material progress on its next-generation spaceship: structural assembly is essentially complete, ground testing starts in April, flight testing is on track for Q3, and the com...
- Structural assembly of the first new spaceship is complete; joining of wing, fuselage, and Bell Textron feather is finishing and weight-on-wheels is expected in the next few weeks.
- Ground testing (production acceptance testing and integrated vehicle ground testing) will begin in April; IVGT expected to wrap in July prior to transport to Spaceport America for flight testing.
- Flight test program is on track to start in Q3 2026, with a partial rocket burn test followed by full-duration burn flights, and the full flight test program extending into Q4 2026.
- +14 more takeaways
Phreesia Q4 FY2026 Earnings Call - Network Solutions visibility trims revenue guide, EBITDA held on AI efficiencies and AccessOne momentum
Phreesia closed FY2026 with clear margin wins and new financial milestones, but the company is downgrading top-line guidance after softer, more variable spend from certain pharmaceutical customers in ...
- Q4 revenue was $127.1 million, up 16% year over year; excluding the AccessOne acquisition, revenue grew 7% YoY.
- Phreesia reported Q4 Adjusted EBITDA of $29.4 million, a 23% margin for the quarter.
- For the full fiscal year, Phreesia surpassed $100 million in Adjusted EBITDA and more than $50 million in free cash flow, and delivered positive GAAP net income for a full fiscal year for the first time.
- +12 more takeaways
Progress Software Q1 2026 Earnings Call - AI-Driven Growth, Record Cash Flow, ShareFile Normalization
Progress delivered a tidy start to fiscal 2026: revenue $248 million, up 4% year over year, ARR roughly $863 million pro forma, up 2%, and EPS $1.60, up 22%. Net retention held at 99% and operating ma...
- Q1 revenue $248 million, up 4% year over year, EPS $1.60, up 22%, operating margin above 41%.
- ARR approximately $863 million pro forma, up 2% year over year; Net Revenue Retention 99%, target is 100%.
- Adjusted free cash flow $99 million, unlevered free cash flow $111 million; record cash generation driven by improved collections.
- +11 more takeaways
Fathom Holdings Inc. Q4 2025 Earnings Call - Structural pricing and ancillary businesses reshaping unit economics
Fathom says 2025 was a year of structural fix, not a weather vane. Revenue climbed 25% to $420.5 million for the year, driven by the My Home Group acquisition and fast-growing ancillary services, but ...
- Full-year 2025 revenue rose 25.4% to $420.5 million, driven largely by the November 2024 acquisition of My Home Group and growth in ancillary services.
- Fourth quarter 2025 revenue declined slightly to $90.6 million, down 1.2% year-over-year, with brokerage revenue down about 3.2% due to softer transaction activity.
- Real estate transactions fell 14.2% year-over-year in Q4 to approximately 8,501 closed transactions; full-year transactions were 42,405, a 14.6% increase driven by the acquisition.
- +12 more takeaways
Lulus Fashion Lounge Q4 2025 Earnings Call - Margin-first turnaround with consecutive positive Adjusted EBITDA and wholesale acceleration
Lulus closed 2025 having reset the cost base and sharpened the assortment, trading top-line pain for a cleaner, more profitable model. Q4 delivered the company’s strongest fourth quarter gross margin ...
- Q4 net revenue was $63.0 million, down 5% year-over-year; full-year 2025 net revenue was $282.3 million, down 11% versus 2024.
- Total orders placed declined 11% in Q4 and 15% for the full year, partially offset by higher average order value, which rose 6% in Q4 and 2% for the year.
- Gross margin expanded to 44.3% in Q4, up 640 basis points year-over-year, the highest fourth quarter gross margin since 2021; full-year gross margin rose to 43.2%, up 200 basis points.
- +14 more takeaways